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Abstract
Background—The MetSyn has been implicated in the development of AF; however, knowledge
of this association among blacks is limited.
Methods—We determined the risk of incident AF through December 2005 in relation to baseline
(1987-1989) MetSyn status in 15,094 participants of the Atherosclerosis Risk in Communities study.
Results—Over a mean follow-up of 15.4 years, 1238 incident AF events were identified. The hazard
ratio (HR) for AF among individuals with, compared to those without, the MetSyn was 1.67 (95%
CI, 1.49-1.87), and associations did not differ by race (p for interaction=0.73). The population
attributable risk of AF from the MetSyn was 22%. The multivariable-adjusted HRs (95% CI) for
each MetSyn component were 1.95 (1.72-2.21) (elevated blood pressure), 1.40 (1.23-1.59) (elevated
waist circumference), 1.20 (1.06-1.37) (low HDL cholesterol), 1.16 (1.03-1.31) (impaired fasting
glucose), and 0.95 (0.84-1.09) (elevated triglycerides). A monotonically increasing risk of AF with
increasing number of MetSyn components was observed, with a HR of 4.40 (95% CI, 3.25-5.94) for
those with all 5 MetSyn components compared to those with 0 components.
Conclusion—In this large cohort, the MetSyn and most of its components were associated with a
higher risk of AF in both blacks and whites. Given the high prevalence of the MetSyn, strategies to
prevent its development or to control individual components may reduce the burden of AF.
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The metabolic syndrome (MetSyn) is defined as a clustering of three or more of the following
atherosclerotic risk factors: abdominal obesity, elevated triglycerides (TG), low high-density
lipoprotein cholesterol (HDL-c), elevated blood pressure, and impaired glucose tolerance.
Although the significance of the MetSyn as a well-defined clinical entity is uncertain, previous
research has implicated this disorder and some of its individual components in the development
of atrial fibrillation (AF).
The mechanisms relating the MetSyn to increased risk of developing AF are not fully
understood. The MetSyn affects atrial anatomy by increasing atrial size, possibly increasing
AF risk as a consequence. Alternatively, the MetSyn may predispose to the development of
coronary heart disease (CHD) or heart failure (HF), in turn increasing the risk of AF.
Knowledge on the association of the MetSyn with AF risk among blacks is limited. Previous
studies have suggested that atrial fibrillation is less common in blacks than whites. However,
it is well known that blacks have a higher prevalence of the MetSyn and most of its components
than do whites. Therefore, our study aimed to determine the association of the MetSyn and its




The Atherosclerosis Risk in Communities (ARIC) study is a prospective investigation aimed
to identify risk factors for atherosclerosis and cardiovascular disease. ARIC recruited adults
aged 45-64 years from four U.S. communities: Forsyth County, NC; Jackson, MS; Minneapolis
suburbs, MN; and Washington County, MD. A total of 15,792 participants (8710 women) were
enrolled from 1987-1989, and completed a home interview and clinic visit. Three triennial
follow-up clinic visits were conducted. In addition, participants are being followed-up by
annual telephone interviews and active surveillance of the ARIC community hospitals. The
ARIC study was approved by institutional review boards at each participating center, and
written informed consent was obtained from all participants.
Atrial Fibrillation Ascertainment
Electrocardiograms (ECGs) during the baseline visit were used to exclude individuals with
prevalent AF or atrial flutter. Incident AF diagnoses through December 31, 2005 were
identified from ECGs performed during study follow-up visits, hospital discharge records, and
death certificates.
All ARIC examination ECGs were recorded using MAC PC Personal Cardiographs (Marquette
Electronics, Inc., Milwaukee, WI). A standard supine 12-lead resting ECG was recorded at
each clinic visit and was transmitted by modem to the ARIC ECG Reading Center for computer
coding. ECG recordings during follow-up that were computer coded as AF were visually re-
checked by a cardiologist.
Annual follow-up telephone calls were placed to cohort participants to identify hospitalizations
and deaths. In addition, local hospitals were surveyed for potential cardiovascular events.
Hospital discharge records were gathered from all hospitalizations, and AF was identified by
an ICD-9 discharge code of 427.31 or 427.32 among any of the discharge diagnoses. AF was
also identified when any listed cause of death on a death certificate was coded as AF (ICD-9
code 427.3 or ICD-10 code I48). AF occurring simultaneously with heart revascularization
surgery (ICD-9 code 36.X) or other cardiac surgery involving heart valves or septa (ICD-9
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code 35.X) was not considered an incident event and follow-up was continued beyond that
episode. Prior analysis within the ARIC cohort to determine the validity of hospital discharge
diagnoses for AF reported 84% sensitivity and 98% specificity in the ascertainment of AF
events.
Metabolic Syndrome Definition
Blood collection and processing techniques for the ARIC study have been previously
described. Enzymatic methods were used to measure TG. HDL cholesterol was measured
enzymatically after dextran sulfate-Mg2+ precipitation of other lipoproteins. Serum glucose
was determined by the hexokinase method. Waist circumference was measured at the umbilicus
level. Blood pressures were measured 3 times in the sitting position after 5 minutes of rest
using a random-zero sphygmomanometer, and the last 2 blood pressure measurements were
averaged.
The MetSyn was defined using the American Heart Association and National Heart, Lung, and
Blood Institute (AHA/NHLBI) criteria as having 3 or more of the following: 1) a waist
circumference of ≥88 cm in women or ≥102 cm in men, 2) fasting TG ≥150 mg/dL (or on lipid
medication), 3) HDL-c <50 mg/dL in women or <40 mg/dL in men (or on lipid medication),
4) blood pressure ≥130/≥85 mmHg and/or a history of treated hypertension, and 5) fasting
glucose ≥100 mg/dL or a history of diabetes (or on diabetes medication). A sensitivity analysis
was conducted setting glucose levels to missing in diabetics. Since results did not differ from
models including diabetics, those with diabetes were included in the elevated fasting glucose
category in all models. However, non-fasters above the cut-point for TG or fasting glucose and
not taking lipid or diabetes medication were set to missing for TG and/or fasting glucose.
Additional Baseline Measurements
Race, years of education, and smoking and drinking status and amount were self-reported. The
sports index for physical activity during leisure time ranged from 1 (low) to 5 (high), and was
based on the questionnaire developed by Baecke et al. A prescription or self-report was used
to determine cholesterol and blood pressure medication use. A fasting glucose ≥126 mg/dL (or
non-fasting glucose of ≥200 mg/dL), a reported physician diagnosis of diabetes, or current use
of diabetes medication categorized a participant as diabetic. Prevalent CHD at baseline
included individuals with a history of myocardial infarction (MI), MI adjudicated from the
baseline ECG, or history of coronary bypass or angioplasty of the coronary arteries. Prevalent
HF was identified using the Gothenburg criteria or self-report of HF medication use in the past
2 weeks.
Statistical Analysis
Analyses were conducted using SAS version 8.2 (SAS Institute, Cary, NC). Of the 15,792
ARIC participants, we excluded races other than black or white (N=48), blacks from
Minneapolis and Washington County (N=55), prevalent AF or atrial flutter identified by the
baseline ECG (N=37), missing or unreadable ECG at baseline (N=309), and unknown MetSyn
status at baseline (N=249).
Person-years of follow-up were computed from the baseline exam until a first AF diagnosis,
death, loss to follow-up, or December 31, 2005. Race-specific baseline participant
characteristics by the MetSyn were compared using chi-squares and t-tests. Overall and race-
specific age- and sex-adjusted incidence rates for AF by the MetSyn status at baseline were
calculated using Poisson regression. Multivariate-adjusted hazard ratios for AF were estimated
in the full cohort and separately by race using Cox proportional hazards regression after
adjusting for the following baseline characteristics: age, sex, race (full cohort analysis), center,
education (less than high school, high school graduate to vocational school, any college),
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smoking status (current, former, never), and smoking amount (pack-years). We estimated
hazard ratios for AF by baseline MetSyn status, individual components of the MetSyn after
additional adjustment for the other components, and by number of MetSyn components in
individuals with known values for all MetSyn components. We also modified our Cox model
allowing for the MetSyn, measured during clinic visits 1-4, as a time-dependent variable.
Multiplicative interactions with sex and race were tested and found to be nonsignificant;
however, we also report race-specific results. We estimated the population attributable risks
of AF from MetSyn and its components using standard methodology. Finally, we used a macro
by Zhang and colleagues to estimate a direct adjusted cumulative incidence curve of AF by
number of MetSyn components at baseline, based on a stratified Cox model. Interaction tests
between the MetSyn and log of follow-up time and the log-log survival curves were plotted to
show that the proportional hazards assumption was met for our Cox regression models.
The Atherosclerosis Risk in Communities Study is carried out as a collaborative study
supported by NHLBI contracts N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-
HC-55019, N01-HC-55020, N01-HC-55021, and N01-HC-55022. This study was also
supported by grants RC1HL099452 from NHLBI and 09SDG2280087 from the American
Heart Association. AMC was supported by NHLBI grant T32-HL-007779. The authors are
solely responsible for the design and conduct of this study, all study analyses, the drafting and
editing of the paper, and its final contents.
Results
After exclusions, 15,094 individuals remained in our dataset. Baseline characteristics of the
study sample are described in Table 1. Those with the MetSyn were less well educated, had
higher mean BMI, were less physically active, and had more comorbidities than did participants
without the MetSyn. At baseline, 45.7% of blacks and 39.6% of whites had the MetSyn (Table
2).
Over a mean follow-up of 15.4 years, 1238 incident cases of AF were identified. The age- and
sex-adjusted incidence rates for AF were 60 and 36 per 10,000 person-years in participants
with and without the MetSyn at baseline, respectively (Table 3). The hazard ratio for AF among
individuals with, compared to those without, the MetSyn was 1.67 (95% CI, 1.49-1.87) overall,
and associations did not statistically significantly differ by race (p for interaction=0.73). The
corresponding population attributable risk (PAR) was 22.0%, indicating that 22% of AF events
could have been prevented with the elimination of the MetSyn, if the association was causal.
Analyses adjusting for heart rate or using MetSyn status as a time-dependent variable did not
appreciably change the associations (data not shown). Further adjustment for BMI as a potential
confounder of the MetSyn and AF association attenuated the estimates (overall HR, 1.42; 95%
CI, 1.25-1.61). Considering only AF events identified in ECGs done at study visits (121 AF
events), the hazard ratio of AF in those with MetSyn compared to those without was 1.96 (95%
CI, 1.36-2.83).
We also stratified our analysis by prevalent CHD and HF at baseline to investigate potential
mediation of the MetSyn and AF association through CHD and HF (Table 3). The prevalence
of the MetSyn was much higher in those with CHD or HF at baseline compared to those without
(70.3% and 38.3%, respectively). For those free of CHD or HF, the association between the
MetSyn and incident AF was similar to that of the entire cohort (HR, 1.53; 95% CI, 1.35-1.74).
The incidence rate of AF among those with prevalent CHD or HF at baseline was higher, but
the hazard ratio for the association of MetSyn with AF was attenuated in comparison to the
entire cohort or the subgroup of participants without prevalent CHD or HF. In a model
excluding those with prevalent CHD or HF and censoring incident CHD or HF during follow-
up, the hazard ratio for AF was also attenuated (HR, 1.30; 95% CI, 1.10-1.54).
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Of the individual MetSyn components, elevated blood pressure appeared to contribute most to
AF risk, corresponding to a two-fold increased risk of AF (Table 4). Elevated waist
circumference conferred a 40% (95% CI, 23%-59%) increased risk, low HDL-c a 20% (95%
CI, 6%-37%) increased risk, and impaired fasting glucose a 16% (95% CI, 3%-31%) increased
risk of incident AF, whereas elevated TG was not associated with AF (HR, 0.95; 95% CI,
0.84-1.09). Elevated blood pressure also had the highest PAR of all MetSyn components at
31.9%. Elevated waist circumference had a PAR of 17.6%, and both low HDL-c and impaired
fasting glucose were 8.1%. A monotonically increasing risk of AF with increasing number of
MetSyn components was observed, with a hazard ratio of 4.40 for those with 5 MetSyn
components compared to those with 0 components. Figure 1 depicts, in the full cohort, higher
cumulative probabilities of incident AF with greater numbers of MetSyn components, with a
cumulative risk of 5.1% among those with 0 components and 20.4% among those with 5
components at baseline.
Discussion
In this population-based prospective study with up to 19 years of follow-up, individuals with
the MetSyn at baseline had a 67% increased risk of incident AF, with similar results in blacks
and whites. The risk of AF increased with each MetSyn component present, and of the
individual components of the MetSyn, elevated blood pressure was the most strongly
associated with AF risk.
Our results are consistent with a prospective study based on annual health checkups in a
Japanese population, which reported a 61% increased risk of AF among individuals with the
MetSyn according to AHA/NHLBI guidelines. They also found all components, except TG,
to increase the risk of incident AF in age- and sex-adjusted analyses. We also found an increased
risk for all components, except TG, even after adjustment for additional confounders and the
other components of the MetSyn. Another small prospective study of patients admitted to a
cardiovascular care center in Japan (32 AF cases, 560 controls) reported a 2.8-fold increased
odds of AF among those with the MetSyn. Obesity/overweight was associated with a 3-fold
greater odds of AF.
Several studies have reported the associations of high blood pressure, diabetes, and obesity
alone with the risk of AF, providing additional evidence that individual components of the
MetSyn are risk factors for AF. The Cardiovascular Health Study reported an 11% increased
risk of AF for each 10 mmHg increase in systolic blood pressure, and a linear trend of increasing
AF risk with increasing systolic and diastolic blood pressure was found in the Women's Health
Study. In the Framingham Heart Study, the odds of developing AF among those with
hypertension was 1.5 in men and 1.4 in women, and the population attributable risk for AF
resulting from hypertension was 14%. In the same study, diabetes was associated with a 1.4
and 1.6-fold increased odds of AF in men and women, respectively. Prospective studies in
other settings have also found an increased risk of AF in diabetics compared to non-diabetics.
Finally, obesity has been implicated in the development of AF: a meta-analysis pooling 5
population-based cohort studies reported a 49% increased risk of developing AF among obese
participants (BMI≥30) compared to nonobese (BMI<30) individuals.
The mechanisms underlying the association between the MetSyn and AF are unclear. The
MetSyn and obesity may increase atrial size, and obesity has also been associated with left
ventricular hypertrophy. Hypertension is associated with left ventricular hypertrophy, impaired
ventricular filling, left atrial enlargement, and slowing of atrial conduction velocity. Finally,
diabetes may cause metabolic stress on the atrium or irritability of the atrium through its
association with systemic illnesses, such as infection or renal failure. In addition, the MetSyn
and its individual components may increase the risk of AF through the development of CHD
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or HF. We found that among individuals with prevalent CHD or HF at the baseline exam, and
also among individuals free of CHD or HF and censoring CHD or HF after the baseline exam,
the associations between the MetSyn and AF were attenuated, suggesting that CHD and HF
may be mediators of the MetSyn and AF association.
The present study has certain limitations that need to be taken into account when reading the
results. First, some incident AF events may have been missed among individuals without
symptoms or who were not hospitalized. Most AF events were ascertained by hospital
discharge records; therefore, underascertainment of events could have led to misclassification
of the events. However, our estimates of AF incidence are similar to those reported by other
cohorts. Further, in a sensitivity analysis including only AF events identified during exam
ECGs, the hazard ratio for AF was similar to the association found when considering all AF
cases. Finally, associations of genetic risk factors and AF in ARIC were similar to other cohort
studies whose identification of incident AF events relied more on study exam ECGs. These
observations suggest that the possible misclassification of the events due to the method of AF
ascertainment was minimal. Second, although we attempted to control for any misclassification
in exposure status by conducting time-dependent analyses, the last exposure measurement
occurred during study visit 4 (1996-98), almost a decade prior to the end of follow-up for AF.
Finally, we did not have information to classify AF as paroxysmal, persistent, or permanent,
eliminating the possibility of conducting sub-group analyses on type of AF. Some strengths of
our study also deserve mention, including the large sample size, long follow-up, high response
rates, racial diversity, and availability of information in a host of potential confounders.
In conclusion, a 67% increased risk of incident AF was seen among individuals with, compared
to those without, the MetSyn during the baseline exam, and the risk of AF increased with greater
number of MetSyn components. Elevated blood pressure appeared to contribute most to AF
risk, although all components except TG were independently associated with an increased risk
of AF. The population attributable risk of AF associated with the MetSyn was 22%. Given
these findings, strategies to reduce the development of the MetSyn or to control its individual
components might reduce the burden of AF.
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Figure 1. Cumulative Probability of Atrial Fibrillation by Number of Metabolic Syndrome
Components at Baseline, ARIC 1987-2005
Figure adjusted for the following covariates at baseline: age (45 to < 50, 50 to <55, 55 to<60,
≥60), sex, race, center, educational attainment, smoking status and cigarette-years of smoking
(quartiles).
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Table 2
Prevalence of Metabolic Syndrome, Individual Metabolic Syndrome Components, and
Number of Metabolic Syndrome Components Present at Baseline by Race, ARIC 1987-89
Blacks Whites
Metabolic Syndrome 1774 (45.7) 4437 (39.6)
Individual Components
 Elevated waist circumference 2373 (61.1) 5630 (50.2)
 Elevated blood pressure 2609 (67.2) 4600 (41.0)
 Elevated triglycerides 653 (17.4) 3641 (32.7)
 Low HDL cholesterol 1298 (33.9) 4801 (42.9)
 Impaired fasting glucose 2086 (54.1) 5223 (46.8)
Number of Components*
 0 333 (9.0) 1628 (14.7)
 1 745 (20.0) 2640 (23.8)
 2 997 (26.8) 2441 (22.0)
 3 932 (25.0) 2129 (19.2)
 4 533 (14.3) 1500 (13.5)
 5 182 (4.9) 756 (6.8)
Values are N(%).
*
Individuals with missing values for any component of the metabolic syndrome were excluded from this analysis, N=14,816.
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Table 4
Overall and Race-Specific Hazard Ratios and 95% Confidence Intervals for Atrial
Fibrillation by the Individual Components of the Metabolic Syndrome and by Number of
Components Fulfilled, ARIC 1987-2005
Overall Blacks Whites
Metabolic Syndrome Components*
 Elevated waist circumference 1.40 (1.23-1.59) 1.50 (1.08-2.09) 1.37 (1.19-1.58)
 Elevated blood pressure 1.95 (1.72-2.21) 1.60 (1.15-2.23) 2.02 (1.76-2.32)
 Elevated triglycerides 0.95 (0.84-1.09) 1.17 (0.84-1.62) 0.93 (0.80-1.07)
 Low HDL cholesterol 1.20 (1.06-1.37) 1.53 (1.14-2.05) 1.14 (0.99-1.32)
 Impaired fasting glucose 1.16 (1.03-1.31) 1.04 (0.78-1.38) 1.18 (1.03-1.35)
Number of Components†
 0 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
 1 1.69 (1.27-2.25) 1.63 (0.70-3.75) 1.71 (1.26-2.33)
 2 2.45 (1.86-3.23) 2.97 (1.35-6.51) 2.37 (1.77-3.19)
 3 2.66 (2.02-3.51) 3.12 (1.42-6.89) 2.60 (1.93-3.50)
 4 3.13 (2.36-4.16) 4.61 (2.07-10.28) 2.90 (2.14-3.94)
 5 4.40 (3.25-5.94) 4.83 (2.00-11.66) 4.30 (3.12-5.94)
*
Multivariate model adjusted for the following covariates at baseline: age, sex, center, educational attainment, smoking status, cigarette-years of
smoking, and the other metabolic syndrome components. Overall model additionally adjusted for race.
†
Multivariate model among individuals without any missing values for metabolic syndrome components. Multivariate model adjusted for the following
covariates at baseline: age, sex, center, educational attainment, smoking status and cigarette-years of smoking. Overall model additionally adjusted
for race.
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